PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
William K. Oh, MD - Mapping the Pathways to Better Patient Outcomes in Prostate Cancer: Personal Insights and Guidance From the Patient CaseBook
Go online to PeerView.com/SEP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the prostate cancer management landscape has become increasingly complex with the approval of several second-generation anti-androgen therapies. Moreover, clinical trials of targeted therapies, immunotherapies, and novel combination regimens are underway across various forms of disease—including nonmetastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. At a recent PeerView Live CaseBook program, a panel of experts presented case vignettes to illustrate the best practice management of prostate cancer and how current clinical trends will change patient care. These case-based interludes highlighted evidence from key trials on next-generation androgen-targeting agents; the role of DNA damage-response mutations; biomarker testing and the potential role of innovative targeted therapy; and advances in immunotherapy for prostate cancer. By providing a “roadmap” to the multiple pathways of prostate cancer management, this program serves as a resource for professionals interested in the present and future applications of new science in patient care. Upon completion of this activity, participants should be better able to: Discuss the clinical outcomes, latest guidelines, and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, cytotoxic, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers, Develop personalized, evidence-based treatment plans for patients in different prostate cancer settings with considerations of tumor-, patient-, and treatment-related factors, Assess the role of genetic testing for treatment decision-making through the prostate cancer disease continuum, Summarize current evidence and ongoing research with investigational strategies, including molecularly targeted and immune checkpoint inhibitor therapies, for the management of prostate cancer.